Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01720602 · ClinicalTrials.gov registry record · NA
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT01720602 is a NA study that has completed, run by University of Washington. The registered enrollment target is 15 participants.
The verdict
NCT01720602, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug.
Interventions
- DRUG letrozole
- DRUG vorinostat
- PROCEDURE positron emission tomography
- DRUG anastrozole
- DRUG exemestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-11 |
| Est. Completion | 2020-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01720602
The ClinicalTrials.gov registry entry for NCT01720602 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which letrozole is the first listed.
NCT01720602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01720602 about?
NCT01720602 is a clinical study titled "Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy". This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug.
What is the current status of trial NCT01720602?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2012-11. Estimated completion is 2020-01.
What interventions are being tested in trial NCT01720602?
The interventions under investigation include: letrozole (DRUG), vorinostat (DRUG), positron emission tomography (PROCEDURE), anastrozole (DRUG), exemestane (DRUG).
Who is sponsoring clinical trial NCT01720602?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.